Gentle vibrations may ease Parkinson's symptoms without surgery
NCT ID NCT05881460
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a wearable device that delivers gentle vibrations to the skin to improve motor function in people with Parkinson's disease. The treatment can be used alongside regular medication and aims to delay the need for higher doses. Thirty participants with moderate-stage Parkinson's will use the device at home for two months, and researchers will measure changes in movement and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2023
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Between the ages of 45-85 2. Diagnosis of idiopathic Parkinson's disease from movement disorders neurologist with the United Kingdom Brain Bank criteria of bradykinesia and one or more of the following: rest tremor, rigidity, and balance problems not from visual, vestibular, cerebellar, or proprioceptive conditions 3. Bilateral, moderate-stage impairment, as defined as Hoehn \& Yahr Stages II-IV in the on-medication state 4. Able to walk and stand unassisted 5. Participants must be on a stable regimen of PD medication (at least 4 weeks prior to enrollment) 6. Responsive to levodopa (self-reported) 7. Willing to keep exercise and medication regimen as stable as possible for the duration of the study 8. Able to provide informed consent 9. Independently, or with social support, able to use technology and access virtual meeting if needed to troubleshoot technology 10. Participants must speak English and can communicate with staff 11. Patients live close to or in the area of where the clinic is located and are able to travel to the clinic for all screening and assessment appointments. Exclusion Criteria: 1. Severe depression or suicide ideation (as assessed with Beck Depression Inventory (BDI), BDI \<28, and Columbia Suicide Severity Rating scale (SSRS), C-SSRS \< 4) \*BDI score \> 28, indicating severe depression that precludes ability to adhere to protocol. Any subject with such a score will be referred to a Primary Care Physician (PCP) or physician for further evaluation and management of depression. Individuals with a BDI score of 17-28 will be excluded if any of the following conditions are met: (1) individual is suicidal, (2) is in need of depression treatment modification currently or (3) depressive symptoms likely to interfere with adherence to study protocol. Any subject with such a score will be referred to a PCP or physician for further evaluation and management of depression. 2. Presence of other neurological or musculoskeletal disorders as determined by the physician during screening. 3. Participation in another drug, device, biologic, or intervention trial concurrently or within the preceding 2-month 4. Physical limitations unrelated to Parkinson's disease 5. Recent change or addition of psychoactive medications for non-parkinsonian treatments 6. Any kind of brain surgery or neurostimulators 7. Pregnancy, breastfeeding, or lack of reliable contraception in women of childbearing age
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Parkinson disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Oregon Health & Science Institution
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Reading the Brain's signals to predict who benefits from deep brain stimulation
- Giving Parkinson's patients a say may boost their Brain's ability to learn movement
- Brain scans probe why some Parkinson's patients freeze Mid-Step
- Can tango rewire the brain? dance program tested for Parkinson's and dementia
- Can a workout after walking practice help Parkinson's patients learn better?